

# People

## Two senior departures at Pharmacopeia

John J. Baldwin, Chief Science and Technology Officer for Pharmacopeia (Princeton, NJ, USA) is retiring from the company at the end of March 2002. However, he will serve as a consultant to the company after his retirement and also expects to continue his scientific work with a start-up company in a related field.

Meanwhile, Bruce C. Myers, Executive Vice-President and Chief Financial Officer of the company is also departing after the Company's Annual Stockholders' meeting in May to pursue other opportunities.

Baldwin was the first employee of Pharmacopeia when it was founded in 1993 and has since held a variety of senior positions leading the company's research efforts.

Joseph A. Mollica, Chairman, President and CEO said that: 'We fully understand his decision to modify his lifestyle, especially given the distance Jack [Baldwin] travels each day to work. Fortunately for us, Jack has built an incredibly talented team of scientists, biologists and scientific management, all of whom I am confident can carry out the same quality of work that we have enjoyed thus far.'

Of the departure of Myers, Mollica said that: 'In addition to his leadership of our finance organization, Bruce has been a key strategic and business advisor over the last few years. We thank him for his hard work and dedication to Pharmacopeia.'

## Robert Tepper appointed to National Advisory Council for Human Genome Research

Robert I. Tepper, Chief Scientific Officer and Executive Vice-President, Discovery at Millennium Pharmaceuticals (Cambridge, MA, USA), has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH).

The council, which consists of 15 members, is responsible for advising the Secretary, the Assistant Secretary for Health, the Director of NIH, and the Director of the National Human Genome Research Institute (NHGRI).

Prior to joining Millennium in 1994, Tepper was Director of the Laboratory of Tumor Biology at Massachusetts General Hospital Cancer Center. He also continues to serve as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital. Mark Levin, CEO of Millennium, commented that: '[Bob's] expertise, experience and profound understanding of molecular medicine will be a valuable contribution to the Council.'

## Hawkins leaves the Department of Energy's Joint Genome Institute for Amersham

Trevor Hawkins has been appointed as Senior Vice-President of Genomics at Amersham Biosciences (Sunnyvale, CA, USA), leaving his role as Director of the Department of Energy's Joint Genome Institute (JGI). In his new role, Hawkins will be responsible for setting the strategic direction of the company's business.

Hawkins originally joined the JGI in 1999 as Deputy Director and was appointed Lawrence Berkeley National Laboratory Genomics Division Director in July 2000 and then became Director of the JGI in November 2000. Prior to this, he was Vice-President of Genomics for CuraGen Corp.

Andrew Carr, CEO of Amersham Biosciences said: 'Trevor Hawkins has established himself as a leader in the industry, and we are delighted to welcome him to our senior management team.'

Carr continued, 'With his proven ability to build and lead complex teams and projects, combined with his first-hand experience of customer needs, Trevor will be an asset in helping the company to realize the value of the considerable investments we have made and will continue to make in the field of genomics.'

## New Director of Biophysics at Astex Technology

Astex Technology (Cambridge, UK) has announced the appointment of Glyn Williams to the position of Director of Biophysics. In this position, Williams will be responsible for implementing biophysical

methods for ligand screening in Astex's lead discovery programs.

Williams previously worked at Roche UK, where he was responsible for Bio-NMR and Mass Spectrometry and for the application of NMR to the structural and dynamic characterization of protein-ligand complexes and the validation of screening results using NMR.

Chief Scientific Officer and co-founder of Astex, Harren Jhoti, said that: 'Williams... brings significant expertise in applying biophysical techniques such as NMR to drug discovery. We are very excited about integrating these complementary biophysical techniques into our high-throughput X-ray crystallography platform to further accelerate our lead discovery and optimization programs.'

## Max Talbott joins Introgen Therapeutics

Introgen Therapeutics (Austin, TX, USA) has announced the appointment of Max W. Talbott to the position of Senior Vice-President, Worldwide Commercial Development, where he will help move the company's product INGN201 from the final stages of development into the market.

Talbott has had over six years of experience with the drug while he led the strategic development and registration plans for it as Senior Vice-President of Regulatory Affairs at Rhone-Poulenc Rorer and Aventis.

David G. Nance, President and CEO of Introgen, commented that: 'Talbott's record of new drug registration and successful market launch of important pharmaceutical products is formidable.'

Talbott has also previously been Senior Vice-President, Worldwide Regulatory Affairs and Pharmacovigilance at Bristol-Myers Squibb Pharma Co. and DuPont Pharmaceuticals Co. He has also previously been Acting Division Director with the US Food and Drug Administration (FDA) and received the FDA Commendable Services Award.

People was written by  
*Rebecca N. Lawrence*